Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Engineering mesenchymal stem cells for immunotherapy

Gene Therapy volume 10, pages 928–931 (2003)Cite this article

Abstract

Allogeneic hematopoietic stem cell transplantation, after sublethal irradiation of recipient animals, is capable of inducing donor-specific tolerance facilitating subsequent organ transplantation. This approach could reintroduce tolerance in autoimmune diseases and it has been applied to treat autoimmune diseases with, however, a great susceptibility of recurrence. Mesenchymal stem cells (MSCs) present within the bone marrow could be critical to the immunosuppressive effect of the treatment. This tolerance induction may be useful in allogeneic transplantations, where low incidence of graft-versus-host disease was observed when the hematopoietic graft was coinjected with MSCs. In this paper, we discuss the use of MSCs in different therapeutic strategies either as immunosuppressive agents or genetically engineered to express molecules acting against the autoimmune process.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Gerber I et al. Hematopoietic stem cell transplantation in systemic sclerosis. The Astis trial. Ann Rheum Dis 2002; 61: S5.

    Google Scholar 

  2. Pittenger MF et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143–147.

    Article  CAS  Google Scholar 

  3. Illei GG, Lipsky PE . Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases. Curr Opin Immunol 2000; 12: 712–718.

    Article  CAS  Google Scholar 

  4. Vermersch P et al. Interferon beta1a (Avonex) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disability. J Neurol 2002; 249: 184–187.

    Article  CAS  Google Scholar 

  5. Pereira RF et al. Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci USA 1995; 92: 4857–4861.

    Article  CAS  Google Scholar 

  6. Colter DC et al. Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc Natl Acad Sci USA 2000; 97: 3213–3218.

    Article  CAS  Google Scholar 

  7. Prockop DJ . Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71–74.

    Article  CAS  Google Scholar 

  8. Noël D et al. Regenerative medicine through mesenchymal stem cells for bone and cartilage repair. Curr Opin Invest Drugs 2002; 3: 1000–1005.

    Google Scholar 

  9. De Bari C et al. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum 2001; 44: 1928–1942.

    Article  CAS  Google Scholar 

  10. Asakura A et al. Muscle satellite cells are multipotential stem cells that exhibit myogenic, osteogenic, and adipogenic differentiation. Differentiation 2001; 68: 245–253.

    Article  CAS  Google Scholar 

  11. Zuk PA et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001; 7: 211–228.

    Article  CAS  Google Scholar 

  12. Erices A et al. Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 2000; 109: 235–242.

    Article  CAS  Google Scholar 

  13. Gronthos S, Simmons PJ . The growth factor requirements of STRO-1-positive human bone marrow stromal precursors under serum-deprived conditions in vitro. Blood 1995; 85: 929–940.

    CAS  PubMed  Google Scholar 

  14. Reyes M et al. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 2001; 98: 2615–2625.

    Article  CAS  Google Scholar 

  15. Deans RJ . Mesenchymal stem cells: cell and gene therapy applications. Eur Cytokine Networks 2000; 11: 323–324.

    CAS  Google Scholar 

  16. Deans RJ, Moseley AB . Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 2000; 28: 875–884.

    Article  CAS  Google Scholar 

  17. Bartholomew A et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42–48.

    Article  Google Scholar 

  18. Di Nicola M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838–3843.

    Article  CAS  Google Scholar 

  19. Saito T et al. Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann Thorac Surg 2002; 74: 19–24; discussion 24.

    Article  Google Scholar 

  20. Devine SM et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001; 29: 244–255.

    Article  CAS  Google Scholar 

  21. Azizi SA et al. Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats –similarities to astrocyte grafts. Proc Natl Acad Sci USA 1998; 95: 3908–3913.

    Article  CAS  Google Scholar 

  22. Kopen GC et al. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci USA 1999; 96: 10711–10716.

    Article  CAS  Google Scholar 

  23. Jin HK et al. Intracerebral transplantation of mesenchymal stem cells into acid sphingomyelinase-deficient mice delays the onset of neurological abnormalities and extends their life span. J Clin Invest 2002; 109: 1183–1191.

    Article  CAS  Google Scholar 

  24. Horwitz EM et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5: 309–313.

    Article  CAS  Google Scholar 

  25. Shizuru JA et al. Purified hematopoietic stem cell grafts induce tolerance to alloantigens and can mediate positive and negative T cell selection. Proc Natl Acad Sci USA 2000; 97: 9555–9560.

    Article  CAS  Google Scholar 

  26. Tyndall A et al. Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000. Ann Rheum Dis 2001; 60: 702–707.

    Article  CAS  Google Scholar 

  27. Moore J et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum 2002; 46: 2301–2309.

    Article  CAS  Google Scholar 

  28. Brinkman DM et al. Decrease in synovial cellularity and cytokine expression after autologous stem cell transplantation in patients with juvenile idiopathic arthritis. Arthritis Rheum 2002; 46: 1121–1123.

    Article  Google Scholar 

  29. Kamiya M et al. Effective treatment of mice with type II collagen induced arthritis with lethal irradiation and bone marrow transplantation. J Rheumatol 1993; 20: 225–230.

    CAS  PubMed  Google Scholar 

  30. Karussis DM et al. Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation. J Immunol 1992; 148: 1693–1698.

    CAS  PubMed  Google Scholar 

  31. Ishida T et al. Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation. Complete prevention of recurrence of autoimmune diseases in MRL/MP-Ipr/Ipr mice by transplantation of bone marrow plus bones (stromal cells) from the same donor. J Immunol 1994; 152: 3119–3127.

    CAS  PubMed  Google Scholar 

  32. Allay JA et al. LacZ and interleukin-3 expression in vivo after retroviral transduction of marrow-derived human osteogenic mesenchymal progenitors. Hum Gene Ther 1997; 8: 1417–1427.

    Article  CAS  Google Scholar 

  33. Marinova-Mutafchieva L et al. Mesenchymal cells expressing bone morphogenetic protein receptors are present in the rheumatoid arthritis joint. Arthritis Rheum 2000; 43: 2046–2055.

    Article  CAS  Google Scholar 

  34. Marinova-Mutafchieva L et al. Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum 2002; 46: 507–513.

    Article  CAS  Google Scholar 

  35. Hunziker EB, Rosenberg LC . Repair of partial-thickness defects in articular cartilage: cell recruitment from the synovial membrane. J Bone Joint Surg Am 1996; 78: 721–733.

    Article  CAS  Google Scholar 

  36. Gazit D et al. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy. J Gene Med 1999; 1: 121–133.

    Article  CAS  Google Scholar 

  37. Harrington K et al. Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery? Hum Gene Ther 2002; 13: 1263–1280.

    Article  CAS  Google Scholar 

  38. Bartholomew A et al. Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum Gene Ther 2001; 12: 1527–1541.

    Article  CAS  Google Scholar 

  39. Studeny M et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon- beta delivery into tumors. Cancer Res 2002; 62: 3603–3608.

    CAS  PubMed  Google Scholar 

  40. Liu L et al. Expression of soluble TNF-RII from transduced human mesenchymal stem cells: in vitro and in vivo efficacy. Blood 1999; 94.

Download references

Author information

Authors and Affiliations

  1. Service d'Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France

    C Jorgensen

  2. INSERM U475, Montpellier, France

    C Jorgensen, F Djouad, F Apparailly & D Noël

Authors
  1. C Jorgensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Djouad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F Apparailly
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Noël
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jorgensen, C., Djouad, F., Apparailly, F. et al. Engineering mesenchymal stem cells for immunotherapy. Gene Ther 10, 928–931 (2003). https://doi.org/10.1038/sj.gt.3302019

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302019

Keywords

This article is cited by

Search

Advanced search

Quick links